Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADICROHN II
2024-517794-24-00Phase 2Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Oct 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing SVF plus microfat with Placebo plus microfat (2 arms). Primary endpoints: Clinical closure of all drained external openings and MRI confirmation of absence of significant collections. Planned start Oct 2024; status: authorised.
02
Drugs
autologous adipose-derived stromal vascular fraction cells
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2024-517794-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517794-24-00.